NRx Pharmaceuticals (NRXP) to Release Quarterly Earnings on Wednesday

NRx Pharmaceuticals (NASDAQ:NRXP) is projected to issue its quarterly earnings data after the market closes on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). On average, analysts expect NRx Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NRx Pharmaceuticals Stock Up 7.3 %

NASDAQ NRXP opened at $2.20 on Wednesday. The company has a 50-day simple moving average of $2.94 and a two-hundred day simple moving average of $2.02. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $6.01. The firm has a market cap of $37.22 million, a price-to-earnings ratio of -1.03 and a beta of 1.22.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Ascendiant Capital Markets increased their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. HC Wainwright reiterated a “buy” rating and set a $19.00 target price on shares of NRx Pharmaceuticals in a report on Friday, March 14th. Finally, D. Boral Capital reiterated a “buy” rating and set a $31.00 target price on shares of NRx Pharmaceuticals in a report on Monday.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.